Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06611254

Quantification of Brain and Kidney Perfusion Before, During, and After Hypothermia Treatment in Neonates With Perinatal Asphyxia Using Contrast-enhanced Ultrasound

In this clinical study vascular dynamics in the neonatal brain and kidney will be monitored by CUES and ULM before, during and after hypothermia treatment in neonates with asphyxia.

Recruiting

Interested in participating?

Request Info

Key information

Sex eligibility

All sexes

Study type

Observational

Primary location

FAU Erlangen-Nuernberg

Erlangen, Bavaria, 91054, Germany

Location status: Recruiting

Location contact

Ferdinand Knieling, MD

CONTACT

[email protected]

0049 9131 85 33118

Ferdinand Knieling, MD

PRINCIPAL_INVESTIGATOR

Gregor Hanslik, MD

PRINCIPAL_INVESTIGATOR

Henriette Mandelbaum

SUB_INVESTIGATOR

About this study

Perinatal asphyxia (PA) is the reduced supply of oxygen to vital organs during or immediately after birth. PA is one of the most common causes of neonatal mortality in full-term infants worldwide and of hypoxic-ischemic encephalopathy (HIE) with subsequent neurological deficits (spastic cerebral palsy). In addition to brain damage, perinatal asphyxia often leads to dysfunction of other organs. It is not uncommon for this to be accompanied by transient renal failure.

Hypothermia treatment is an established therapeutic measure for neuroprotection in clinical indications of HIE. This involves lowering the core body temperature of affected children to 33.5°C for 72 hours. The therapeutic effect is thought to be due to multifactorial mechanisms, including a reduction in endothelial dysfunction, reduced excretion of free radicals and attenuation of the inflammatory cascade.

In the guidelines for hypothermia treatment in neonatal asphyxia, regular ultrasound examinations are prescribed to clarify damage to the central nervous system (CNS) before, during and after hypothermia treatment.1 In infants, transfontal ultrasound makes it possible to visualize brain structures, vessels and their flow velocities.

The intravenous use of ultrasound contrast enhancers as an aid also opens up the possibility of recording the tissue perfusion of the CNS and kidneys, including the smallest vessels.8 This could provide significantly more information compared to conventional methods and expand our knowledge of the pathophysiology and individual status of tissue perfusion in patients.

For example, two studies at Erlangen University Hospital have successfully used contrast-enhanced ultrasound (CEUS) with the contrast agent known as SonoVue® to visualize postoperative perfusion of the brain after pediatric cardiac surgery.

In this clinical study, the new CEUS measurement and imaging technique will be used before, during and after hypothermia treatment in neonates with asphyxia. A contrast agent (SonoVue®) will be administered during the routine ultrasound examination and improved tissue visualization will be achieved. The aim is to gain new insights into brain and kidney perfusion as part of the treatment and to better assess the extent of organ damage in the individual patient through more specific vascular imaging. Improved visualization and assessment of the end-stream area will provide information on processes that promote the development of HIE and renal failure. Finally, the aim is to compare diagnostic and prognostic methods with the currently recommended measures. The CEUS is to be examined as a possible diagnostic imaging tool and possibly a supplement to existing diagnostic methods.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Fulfillment of the inclusion criteria for hypothermia treatment according to the AWMF guideline
  • Severe acidosis (pH ≤7.0 or a base deficit ≥16 mmol/l) in umbilical cord blood or a blood sample from the first hour of life, and
  • clinical signs of moderate or severe encephalopathy (severity grade 2 or 3 according to Sarnat & Sarnat), and
  • postnatal age ≤6h, and
  • gestational age ≥36 weeks' gestation
  • Consent of the parents/legal guardians
  • Time 1 (before the start of hypothermia treatment)
  • Informing the parents/legal guardians present on site despite an emotionally stressful situation with high individual benefit for the patient
  • If only one parent is present and able to provide information, their consent is sufficient - the second parent is informed repeatedly when they regain the ability to provide information
  • Information adapted to the emergency situation, addressing the personal situation and comprehensible presentation of the plan
  • Time 2 (during hypothermia treatment)

-->Offer of a further informative discussion/repeated explanation with the parents/legal representatives before the second measurement in order to answer any questions that may have arisen

  • Suitable acoustic window
  • Availability of the qualified examiner

Exclusion criteria

  • Lack of consent of at least one parent
  • Pre-existing brain malformations
  • Absence of the competent examiner

Treatment and study plan

Contrast enhanced ultrasound imaging (CEUS) and post processing with ULM

Device

CEUS is a contrast based ultrasound technique and ULM (Ultrasound Localization Microscopy) is a post-processing bioinformatical method to quantify microvascular architecture and perfusion dynamics.

Primary outcomes

  1. CEUS Time intensity curves

    Time frame: before(T1, within the first 6hours of life), during hypothermia treatment(T2, 6-78hours of life), after treatment (T3, within first week of life)

    All CEUS outcomes will be generated in order to achieve time intensity curves in contrast enhanced ultrasound analysis

  2. CEUS Measurement1

    Time frame: before(T1, within the first 6hours of life), during hypothermia treatment(T2, 6-78hours of life), after treatment (T3, within first week of life)

    PE (Peak-Enhancement)

  3. CEUS Measurement2

    Time frame: before(T1, within the first 6hours of life), during hypothermia treatment(T2, 6-78hours of life), after treatment (T3, within first week of life)

    WiAUC (Wash-in Area Under the Curve (AUC(TI: TTP)))

  4. CEUS Measurement3

    Time frame: before(T1, within the first 6hours of life), during hypothermia treatment(T2, 6-78hours of life), after treatment (T3, within first week of life)

    WiAUC (Wash-in Area Under the Curve (AUC(TI: TTP)))

  5. CEUS Measurement4

    Time frame: before(T1, within the first 6hours of life), during hypothermia treatment(T2, 6-78hours of life), after treatment (T3, within first week of life)

    RT (Rise Time)

  6. CEUS Measurement5

    Time frame: before(T1, within the first 6hours of life), during hypothermia treatment(T2, 6-78hours of life), after treatment (T3, within first week of life)

    mTT (mean Transit Time local) (mTT-TI))

  7. CEUS Measurement6

    Time frame: before(T1, within the first 6hours of life), during hypothermia treatment(T2, 6-78hours of life), after treatment (T3, within first week of life)

    TTP (Time to Peak)

  8. CEUS Measurement7

    Time frame: before(T1, within the first 6hours of life), during hypothermia treatment(T2, 6-78hours of life), after treatment (T3, within first week of life)

    WiR (Wash-in-Rate )

  9. CEUS Measurement8

    Time frame: before(T1, within the first 6hours of life), during hypothermia treatment(T2, 6-78hours of life), after treatment (T3, within first week of life)

    WiPI (Wash-in Perfusion Index (WiAUC/RT))

  10. CEUS Measurement9

    Time frame: before(T1, within the first 6hours of life), during hypothermia treatment(T2, 6-78hours of life), after treatment (T3, within first week of life)

    WoAUC (Wash-out AUC (AUC(TTP:TO)))

  11. CEUS Measurement10

    Time frame: before(T1, within the first 6hours of life), during hypothermia treatment(T2, 6-78hours of life), after treatment (T3, within first week of life)

    WiWoAUC (Wash-in- und Wash-out-AUC (WiAUC+WoAUC))

  12. CEUS Measurement11

    Time frame: before(T1, within the first 6hours of life), during hypothermia treatment(T2, 6-78hours of life), after treatment (T3, within first week of life)

    FT (Fall Time - (TO-TTP))

  13. CEUS Measurement12

    Time frame: before(T1, within the first 6hours of life), during hypothermia treatment(T2, 6-78hours of life), after treatment (T3, within first week of life)

    WOR (Wash-out-Rate) QOF (Quality Of Fit between the echo-power signal and f(t)

  14. CEUS Measurement13

    Time frame: before(T1, within the first 6hours of life), during hypothermia treatment(T2, 6-78hours of life), after treatment (T3, within first week of life)

    QOF (Quality Of Fit between the echo-power signal and f(t)

  15. Near-infrared spectroscopy

    Time frame: before(T1, within the first 6hours of life), during hypothermia treatment(T2, 6-78hours of life), after treatment (T3, within first week of life)

    Near-infrared spectroscopy Non-invasive measurement of oxygen saturation in tissue using a probe that is attached to the head.62 This procedure is already firmly established in the field of pediatric surgery and pediatric cardiology interventions at the University Hospital Erlangen. The probe is attached before the start of the first measurement time point and removed after the end of the third measurement time point. There is no risk of side effects.

  16. Visualization and quantification of cerebral perfusion with CEUS

    Time frame: before(T1, within the first 6hours of life), during hypothermia treatment(T2, 6-78hours of life), after treatment (T3, within first week of life)

    CEUS imaging for cerebral perfusion in asphyxia

  17. Visualization and quantification of of renal perfusion with CEUS

    Time frame: before(T1, within the first 6hours of life), during hypothermia treatment(T2, 6-78hours of life), after treatment (T3, within first week of life)

    CEUS imaging for renal perfusion in asphyxia

Secondary outcomes

  1. CEUS and NIRS

    Time frame: T1,T2,T3

    Correlation coefficient (R) between CEUS curve and NIRS

  2. Neurological status assessment (Bayley Score)

    Time frame: Month of life: 3-4 and 6-24

    Neurological status of the patients will be assessed by the score "Bayley Scales of Infant and Toddler Development"

  3. MRI imaging in asphyxia

    Time frame: once within first two years of life

    MRI Weeke Score

  4. Comparison of the CEUS time-intensity curve between three timepoints

    Time frame: T1,T2, T3

    CEUS curve at T1,T2, T3

  5. Assessment of blood Lactate

    Time frame: T1, T2, T3

    Lactate (mmol/l)

  6. EEG signs of seizures

    Time frame: T1 -T3 and through study completion

    Number (n) of ETPs in EEG

  7. EEG activity

    Time frame: T1 -T3 and through study completion

    frequency EEG (Hz)

  8. Assessment of renal function GFR

    Time frame: T1 -T3 and through study completion, an average of 3 years

    GFR (ml/min/1,73 m2)

  9. Assessment of renal function urea

    Time frame: T1 -T3 and through study completion, an average of 3 years

    urea (mg/dl)

  10. Assessment of renal function urinary status

    Time frame: T1 -T3 and through study completion

    standardized urinary status

  11. Assesment of renal function kreatininekinase

    Time frame: T1, T2, T3

    kreatininekinase (U/l)

  12. Assessment of metabolic LDH

    Time frame: T1, T2, T3

    LDH (U/l)

Study contacts

Contact information is provided by the study sponsor or research team.

Ferdinand Knieling, MD

CONTACT

[email protected]

0049 9131 85 33118

Gregor Hanslik, MD

CONTACT

[email protected]

0049 9131 85 33118

Sponsors and collaborators

Lead sponsor

University of Erlangen-Nürnberg Medical School

Other

Registry information

Important dates

Study start
2024
Primary completion
2027
Study completion
2027
First posted
Sep 24, 2024
Registry last updated
Sep 24, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.